Tumor cell glycosylated receptors and integrins

Tumor cell glycosylated receptors and integrins encompass a diverse group of cell surface molecules that are frequently dysregulated in malignancy. Integrins are heterodimeric transmembrane proteins that bridge the extracellular matrix to the intracellular cytoskeleton, playing a pivotal role in cell survival, migration, and the angiogenic switch required for tumor growth (Desgrosellier & Cheresh, 2010, Nature Reviews Cancer). Glycosylated receptors, such as the epidermal growth factor receptor (EGFR), often exhibit altered carbohydrate structures in cancer cells, which can enhance signaling potency and protect the receptor from proteolytic degradation (Pinho & Reis, 2015, Nature Reviews Cancer). These molecules serve as critical therapeutic targets because their overexpression or structural modification is often correlated with poor prognosis and metastatic potential. Therapeutic strategies targeting these entities include monoclonal antibodies, small molecule inhibitors, and RGD-mimetic peptides designed to block adhesion and induce apoptosis in tumor cells. Understanding the interplay between glycosylation patterns and integrin function is essential for developing precision medicines that can selectively disrupt the tumor microenvironment.

Other names

Tumor-associated glycoproteinsCell surface integrinsCancer-associated glycosylated receptorsTumor cell surface adhesion molecules

Inhibition of ligand binding to cell surface receptors, disruption of cell-extracellular matrix interactions, and modulation of downstream oncogenic signaling pathways.